(Bloomberg) -- GSK Plc shares surged after the UK pharma company agreed to pay as much as $2.2 billion to resolve about 80,000 US court cases alleging that its old reflux medication Zantac was ...

Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

GSK has reached an agreement that it says will resolve 93% of the outstanding lawsuits brought against the company claiming that its gastrointestinal drug Zantac caused cancer. The company has ...

GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen.

Operating profit at GSK fell by 86 per cent due to a charge related to the settlement of Zantac settlements the company said ...

GSK shares jumped as much as 6.5% on Thursday after the British drugmaker struck a $2.2 billion settlement over U.S. lawsuits that alleged its discontinued heartburn drug Zantac caused cancer.

British pharmaceutical company GSK on Wednesday said it swung into a net loss in the third quarter after settling lawsuits in the United States surrounding its Zantac heartburn drug. GSK suffered ...

GSK is on track to achieve its guidance for 2024, with its Q3 2024 and 9m 2024 results today. Explore more details here.

Zantac’s manufacturers were on a roll. Their defense had exacted a spate of favorable decisions and jury verdicts. Yet, on October 9, Glaxo Smith Kline (GSK) suddenly settled 93% of the remaining ...

GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...

GSK (GSK) stock was downgraded by Guggenheim Securities to neutral after the company's Q3 revenue decline. Read more here.